Norris Medicines Ltd Financials
Company Logo

Norris Medicines Ltd Financial Statement

Norris Medicines Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue1.48
Operating Expense1.56
Net Profit-0.31
Net Profit Margin-20.95
Earning Per Share-0.31
EBIDTA-0.08
Effective Tax RateTBA

Norris Medicines Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual5.82
Operating Expenses Annual6.08
Operating Profit Annual-0.20
Interest Annual0.44
Depreciation0.54
Net Profit Annual-1.24
Tax Annual0.06

Norris Medicines Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.04
Cash Flow from Operations0.51
Cash Flow from InvestingTBA
Cash Flow from Financing-0.50
Cash Flow at the End0.04

Norris Medicines Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)-3.44
PBIT Margin (%)-12.71
PBT Margin (%)16.16
Net PROFIT Margin (%)-21.31
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-17.04
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.80

Norris Medicines Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual5.27
Total Current Assets Annual6.34
Non Current Assets Annual7.47
Total Shareholders Funds Annual-14.87
Total Assets Annual13.81

Norris Medicines Ltd Earning Calls

No Data Availabe

FAQS on Norris Medicines Ltd Financials

As of Oct 7, 2025, Norris Medicines Ltd has a market capitalization of 16.78 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Norris Medicines Ltd is with a debt-to-equity ratio of -1.45.

In FY 2024 , Norris Medicines Ltd recorded a total revenue of approximately 5.82 Cr marking a significant milestone in the company's financial performance.

Norris Medicines Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.2% annually, respectively..

Norris Medicines Ltd's current PE ratio is -13.53.

Norris Medicines Ltd's ROCE averaged -5.6% from the FY ending March 2023 to 2025, with a median of -9.2%. It peaked at 3.4% in March 2023, reflecting strong capital efficiency over the period..

Norris Medicines Ltd's latest EBIT is Rs. -0.74 Cr, surpassing the average EBIT of Rs. -0.39 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions